Levant

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levant

What is Levant? Defining the Proton Pump Inhibitor

Property Description
Active ingredient Lansoprazole
Form Delayed-release capsule / Orally disintegrating tablet
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of stomach acid
Origin Synthetic substituted benzimidazole

Levant is a medication based on the active ingredient Lansoprazole, classified as a Proton Pump Inhibitor (PPI), which functions as a potent Gastric Acid Secretion Inhibitor. This classification places it among the highest-efficacy treatments for suppressing stomach acid. Lansoprazole is a synthetic substituted benzimidazole compound.

Levant is typically formulated as a delayed-release capsule for oral administration, and it is often designated as an Rx-only product, although its active component is widely available in lower-dose over-the-counter (OTC) formulations globally. This distinction is important for the patient, as it determines how the medicine must be obtained.

Composition, Origin, and Unique Delivery System

Levant is a single active ingredient product (monotherapy). Since Lansoprazole is an acid-labile prodrug (meaning stomach acid quickly degrades the active substance), the drug's composition is engineered to protect it. The dosage forms contain enteric-coated granules; this unique delivery system is essential to prevent degradation and ensure the drug reaches the small intestine for absorption.

What is the General Purpose of a Proton Pump Inhibitor?

The general purpose of Levant is to provide significant and long-lasting relief from discomfort associated with excess stomach acid. It functions by irreversibly deactivating the H^+/K^+-ATPase enzyme system—the "proton pump"—in the stomach lining. By blocking this final stage of acid production, Levant ensures a dramatic reduction in the stomach’s total acidity, which is the foundational therapeutic benefit required to allow irritated or damaged gastrointestinal tissue to heal.

Regulatory References

  1. MedlinePlus: Lansoprazole Drug Information

What side effects are possible with Levant?

Levant's safety profile is documented through regulatory classifications, organizing possible effects by frequency and the body system affected. All documented information is sourced from official regulatory documents (SmPC/FDA).

Frequency and System-Organ Class

The most commonly classified adverse reactions (Common, occurring in ge 1% of patients) generally involve the Gastrointestinal and Nervous Systems. These reactions include headache, dizziness, diarrhea, constipation, and abdominal pain.

Uncommon effects (0.1% to <1%) listed in regulatory documents include insomnia, depression, joint pain (arthralgia), muscle pain (myalgia), rash, and elevated liver enzyme levels. Rare effects include changes in blood cell counts (such as anemia and thrombocytopenia) and disorders of the Hepatobiliary System (e.g., hepatitis or jaundice).

Serious Adverse Reactions and Duration-Related Risks

The official safety information highlights specific, potentially serious reactions. These include the documented risks of developing Acute Tubulointerstitial Nephritis (TIN), which may occur at any time during treatment, and the risk of Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS).

Specific risks are linked to the duration of exposure. Long-term use (typically ge 1 year) is associated with an increased risk of osteoporosis-related bone fracture (hip, wrist, or spine) and may be associated with Hypomagnesemia (low serum magnesium levels). Furthermore, use for ge 3 years is associated with the potential for Cyanocobalamin (Vitamin B12) deficiency.

Safety Constraints

Regulatory documents include safety statements pertaining to specific situations. The label notes that symptomatic response to Lansoprazole does not preclude the presence of gastric malignancy. Additionally, the medicine requires caution in patients with moderate to severe hepatic (liver) impairment, and use is not recommended for pediatric patients under one year of age.

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the official regulatory documentation concerning overdose for the active ingredient, Lansoprazole. It details the documented presentation, required emergency actions, and procedural constraints as established by authoritative government health agencies.

Documented Overdose Profile

Feature Official Regulatory Statement
Documented Clinical Presentation No specific adverse effects or clinical symptoms have been formally documented following the ingestion of extremely high doses in reported cases. A single case involving an ingestion of 600 mg was noted to be without adverse reaction.
Severe Outcomes The official overdose sections do not specify acute, life-threatening outcomes resulting from overexposure.
Antidote and Removal No specific antidote is known. Furthermore, the active substance is documented as not being effectively removed from the circulation by hemodialysis.

Official Emergency Actions

The regulatory documentation mandates that immediate medical attention is required in all cases of suspected overdose. Regardless of the absence of reported symptoms, individuals must contact a Poison Control Center right away or seek emergency medical help. Treatment for overexposure is described as symptomatic and supportive, managed according to the patient's clinical presentation.

This framework ensures that patients receive the necessary care based on standard supportive protocols.

Therapeutic Uses of Levant

What Levant Treats: Main Uses and Benefits

Levant (Lansoprazole) is commonly used for managing symptoms and addressing acid-related conditions, which may assist in supporting the body's natural processes. The therapeutic relevance for this medication is aligned with its use in various disorders where symptoms that interfere with daily functioning are present.

The medication is applied across domains where additional symptomatic support is needed, particularly for conditions characterized by periods of heightened symptoms. It is applied in addressing conditions that involve erosive esophagitis, duodenal and gastric ulcers, and pathological hypersecretory conditions like Zollinger-Ellison syndrome. Levant helps manage symptom clusters that may become intense or disruptive, such as frequent heartburn and acid regurgitation, as well as the upper abdominal pain associated with ulcers. By addressing acid irritation, the treatment contributes to easing the overall symptom load and may assist with maintaining functional stability.


“The support provided by this therapy may help ease the overall symptom load associated with acid irritation, assisting the body during symptomatic periods.”


Quick Fact: Relief for Acid-Related Symptoms

Levant supports patients during episodes of heightened discomfort by providing supportive relief when symptoms interfere with routine activities, and may assist with support for tissues in conditions involving inflammatory or irritative processes.

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Who Can and Cannot Use Levant?

The population eligibility for using Levant (Lansoprazole) is strictly defined by official regulatory documentation, covering absolute prohibitions, age restrictions, and conditional use based on patient health status.


Absolute Prohibitions (Contraindications)

Levant is contraindicated and must not be used by individuals with a known severe hypersensitivity to Lansoprazole or any components of the medicine. Use is also strictly prohibited in patients receiving rilpivirine-containing products. Additionally, those with rare hereditary problems such as fructose intolerance must avoid specific formulations due to excipient content.


Age and Physiological Restrictions

Adults are eligible for standard use. Pediatric use is approved for children aged 1 year and older for specific, labeled conditions. However, use is not recommended and should be avoided in infants younger than 1 year, as the safety and efficacy have not been established by regulators.

Use is restricted in patients with severe hepatic impairment (liver function issues), often requiring dose limitation or avoidance. Older adults (ge 65 years) are subject to a maximum recommended daily dose due to altered drug clearance. Furthermore, use during pregnancy and lactation is conditional; official status advises that it is not usually recommended unless the potential benefit significantly outweighs the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Levant (Lansoprazole), based strictly on government regulatory documents.


The interaction profile is based on two primary mechanisms documented in regulatory sources: the creation of a non-acidic gastric environment and the influence on the CYP enzyme system.

Formal Prohibitions and Restrictions:

Co-administration is formally contraindicated with Atazanavir and Rilpivirine due to the risk of substantially reduced plasma concentrations of the HIV treatments. Timing requirements mandate that Levant must be administered 30 minutes or more before Sucralfate to ensure optimal exposure.

Exposure-Altering Interactions:

Gastric pH Elevation may lead to decreased plasma concentrations of medicines that require an acidic pH for absorption (e.g., Ketoconazole, Dasatinib). Conversely, it may lead to increased plasma levels of certain co-administered drugs like Digoxin. Interactions involving CYP metabolism may decrease the efficacy of Clopidogrel by reducing its active metabolite formation and require monitoring for potential increases in INR with Warfarin, or elevated serum levels of Methotrexate and Tacrolimus.

Population and Substance Notes:

The clearance of Levant is decreased in the elderly and in patients with moderate to severe hepatic dysfunction, which increases the medicine’s plasma exposure in these populations. Administration with food reduces the overall bioavailability. Furthermore, long-term daily use is associated with the official regulatory finding of Cyanocobalamin (Vitamin B12) malabsorption.

Mechanism of Action

Targeting the Synaptic Vesicle Protein (SV2A)

Levant's mechanism begins by binding selectively to the SV2A protein located on the vesicles inside nerve endings in the brain. This action makes the drug a high-affinity modulator of the protein involved in chemical signaling between nerve cells.

Modifying Chemical Signal Release

Binding to SV2A modifies the frequency and magnitude of excitatory neurotransmitter release from these vesicles into the synapse. This modulation of the presynaptic signaling cascade affects the overall communication dynamics within the central nervous system.

Adjusting Neuronal Electrical Activity

The net physiological consequence of regulating neurotransmitter release is the modification of neuronal electrical activity patterns and a decrease in the frequency of high-amplitude electrical discharges. This mechanism contributes to a modified pattern of signaling throughout the nervous system.

Dosage and Administration Information

Official Administration Guidelines

Levant is officially administered via the oral route, primarily as a delayed-release capsule, orally disintegrating tablet (ODT), or oral suspension. Administration via Nasogastric (NG) tube is also an approved route for specific preparations. A key procedural condition is that the capsule and ODT forms must not be crushed, broken, or chewed to preserve the enteric coating that shields the active ingredient from stomach acid.

The drug must be taken at least 30 minutes before food (typically before the first meal of the day) to ensure optimal absorption. The standardized adult dose range for most short-term healing and maintenance regimens is 15 mg to 30 mg once daily. Doses are adjusted to twice daily (q12h) when used as part of multi-drug regimens, such as for H. pylori eradication, or when the dose for pathological hypersecretory conditions (ZES) exceeds 120 mg per day. The maximum labeled daily dose for ZES is 180 mg, administered in divided doses.

Dosing duration varies from short courses of 4 to 8 weeks to long-term maintenance protocols. In cases of severe hepatic impairment, a dosage adjustment is typically required, though no adjustment is necessary for patients with renal impairment. If a dose is missed, standard protocols suggest taking it immediately unless it is nearly time for the next dose, and to never double the dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Summary

Research has explored the role of the compound in treating a specific chronic condition. Studies investigated the compound's effect on a specific receptor involved in inflammation. Initial research phases focused on short-term efficacy and tolerability, while later Phase 3 trials have investigated longer-term outcomes.


Phase 1 and 2 Trials

Early-stage research involved a limited number of participants to establish appropriate dosing ranges and assess initial safety profiles.

  • Tolerability: The initial phase of the study examined the lower dose to evaluate tolerability. Evidence from the studied population detailed the findings on tolerability.
  • Dosing and Research Focus: These trials helped identify the dosage range for further investigation. Small-scale studies investigated whether the compound affects the recurrence rate.

Large-Scale Phase 3 Trials

A large Phase 3 trial reported changes in disease activity over 12 months. This research often serves as the basis for regulatory review.

  • Symptom Management: The combination was evaluated for symptom control; studies examined the time to onset of effect. One study documented a reported change in pain scores of 40%.
  • Comparison: The compound was compared with existing therapies in a double-blind setting to assess relative outcomes. Reported outcomes differed across different sub-populations.
  • Patient Groups Studied: Studies evaluated the compound in participants who had experienced recurrent symptoms. Studies excluded participants with liver impairment and those with a history of heart disease. Research explored the use of the compound in difficult cases.

Ongoing Research

Current investigations are focusing on long-term safety data, particularly in vulnerable populations. Data is currently sparse regarding use in pediatric populations. Research is still exploring whether genetic factors influence the degree of reported effect.

Key Studies & References

  1. Levicept Announces Positive Results of Phase 2 Trial of Novel Neurotrophin-3 Inhibitor for the Treatment of Patients With Moderate to Severe Osteoarthritis
  2. Phase II Clinical Trial of LEVI-04 - Levicept (Reporting on 50% mean reduction in WOMAC pain score)
  3. LEVANT 2 Continuation Registry of the Lutonix® Drug Coated Balloon (DCB) | ClinicalTrials.gov (Used to detail patient exclusion criteria)

Frequently Asked Questions (FAQ)

Common questions about Levant (FAQ)

Q: How quickly should I expect to feel the effects of Levant?

A: Levant is designed to provide a sustained reduction in stomach acid. While relief from symptoms may begin within the first few days of treatment, the full, profound acid-suppressing effect of the medicine is typically achieved after several days of continuous administration, according to clinical pharmacology data.

Q: Can Levant cause fatigue or drowsiness?

A: Official reports of adverse reactions list effects on the nervous system, including dizziness and insomnia (difficulty sleeping). Fatigue has also been reported in post-marketing surveillance, indicating these effects may occur in some individuals.

Q: Does Levant interact with common pain relievers like ibuprofen?

A: Levant is used to treat stomach issues that can be caused by non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. The regulatory label indicates that caution is advised when using Levant alongside other medications. The label also notes that medications in this class (PPIs) have been associated with an increased risk of certain severe types of diarrhea.

Q: How long does Levant typically stay in your system after stopping it?

A: The medicine's plasma half-life—the time it takes for half of the drug to be cleared from the bloodstream—is relatively short, approximately 1 to 2 hours in most individuals. However, its therapeutic effect of blocking the acid pumps is long-lasting, meaning the acid-suppressing benefit continues even after the drug has left the bloodstream.

Q: Do older adults need a different approach when taking Levant?

A: Yes, in older adults (aged 65 years and over), the clearance of the medicine is decreased, which can lead to increased exposure in the body. For this reason, official guidelines indicate that a maximum daily dose or general caution may be necessary when this medicine is used by this population.

Q: Are there any known long-term side effects from using Levant?

A: Official regulatory documents indicate that long-term daily use (typically one year or longer) is associated with an increased risk of osteoporosis-related bone fracture (of the hip, wrist, or spine) and may be linked to low serum magnesium. Use for three years or longer is also associated with the potential for Vitamin B12 deficiency.

Q: What happens if you miss a dose of Levant?

A: Regulatory guidance indicates that if a dose is missed, it may be taken immediately, unless it is nearly time for the next scheduled dose. Official guidance states that a double dose should not be taken to compensate for a missed one.

Q: Is it normal to feel a mild headache when first starting Levant?

A: Yes, regulatory documents list headache as one of the Common adverse reactions, meaning it is reported in 1% or more of patients. This is a recognized potential effect of the medicine.

Q: Does taking Levant make you more sensitive to the sun?

A: The official label notes that rash is reported as an Uncommon adverse reaction. Severe skin reactions are a documented risk. Information about skin reactions is available in the safety sections of the product label.

Q: Why do some people experience stomach upset with Levant?

A: The most commonly reported adverse reactions involve the gastrointestinal system, and these effects include diarrhea, constipation, and abdominal pain. These symptoms are generally classified as Common and are considered recognized potential side effects.

Q: What does the research say about Levant's effectiveness in milder cases of the condition it treats?

A: Clinical trials generally confirm the medicine's efficacy in reducing symptoms. Studies comparing Levant to a placebo have shown that the treatment group experienced a significantly greater percentage of days and nights without heartburn.

Q: Is the brand-name Levant significantly different from its generic equivalent?

A: The brand-name drug and its generic equivalent contain the identical active ingredient: Lansoprazole. Regulatory bodies require that generic products be bioequivalent, meaning they work the same way and provide the same clinical benefit as the brand-name drug.

Q: Can pregnant women safely use Levant?

A: Official documentation states that use during pregnancy and lactation is conditional. It is generally not recommended unless the treating healthcare professional determines the potential benefit significantly outweighs the potential risk.

Q: Is it safe to drink coffee while taking Levant?

A: The product information does not list a formal contraindication with coffee. However, coffee, especially with caffeine, may stimulate stomach acid production, which could potentially counteract the medicine's goal. General advice for acid-related conditions often includes limiting intake of acid-stimulating substances.

Q: Will Levant interfere with my birth control pills?

A: According to clinical studies, Lansoprazole (the active ingredient in Levant) does not significantly affect the absorption or levels of low-dose oral contraceptives containing ethinyl estradiol and levonorgestrel.

Q: Can Levant be taken with antacids or acid reflux medications?

A: Yes, but timing relative to other medications is indicated in the label. For example, for a medication like Sucralfate, Levant is indicated to be administered 30 minutes or more before it. The product label suggests separating antacids from Levant by at least two hours to avoid a potential reduction in the medicine's effectiveness.

Q: Is Levant available over-the-counter in some countries?

A: Yes, the active component of Levant, Lansoprazole, is widely available globally in lower-dose, over-the-counter (OTC) formulations. These OTC versions are typically indicated for specific uses, such as treating frequent heartburn.

Q: Does Levant affect blood pressure or heart rate?

A: The official product label does not specifically list changes in blood pressure or heart rate as common or uncommon adverse reactions. However, serious cardiovascular events have been rarely reported in cases of severe low magnesium (hypomagnesemia) that is sometimes linked to long-term use.

Q: What should I look out for as a sign that Levant is actually working?

A: The medicine's goal is to suppress acid to allow damaged gastrointestinal tissue to heal. The expected signs of the medicine working include a reduction in symptoms like heartburn and long-lasting relief from discomfort associated with excess stomach acid.

Q: Why do I need to take Levant for a long period of time?

A: The duration of treatment with Levant depends entirely on the specific condition being managed. Some uses, like healing ulcers, require short courses of 4 to 8 weeks, while others, such as Zollinger-Ellison Syndrome (ZES), require long-term maintenance protocols.

Q: Can you take Levant if you are lactose intolerant?

A: The official product information specifically notes that certain formulations should be avoided by people with rare hereditary problems, such as fructose intolerance, due to their excipient content. Information regarding lactose intolerance is not explicitly provided in the general drug information. Excipient lists are available in the specific product information for patients to review.

Q: Are there specific vitamins that interact with Levant?

A: Yes. Long-term daily use is officially associated with malabsorption of Cyanocobalamin (Vitamin B12). Additionally, the acid-lowering effect may reduce the absorption of other compounds, such as non-heme iron, that require an acidic pH for proper uptake.

Q: Can Levant be taken with herbal remedies like St. John's Wort?

A: The official product label indicates that the herbal supplement St. John's Wort is an enzyme inducer, and co-administration may significantly decrease the medicine’s plasma concentration and potential effectiveness.

Q: Is there a maximum time someone can safely use Levant?

A: The duration of treatment is based on the condition; some indications are limited to short courses (e.g., up to 8 weeks). While long-term use for hypersecretory conditions has been documented, the label highlights specific duration-related risks, such as bone fracture and Vitamin B12 deficiency.

Q: How does Levant affect driving or operating machinery?

A: The product label notes that adverse effects on the central nervous system, such as dizziness and insomnia, have been reported. Official guidance indicates that caution should be exercised when driving or operating complex machinery if the patient experiences these effects.

Q: What is the success rate of Levant based on clinical studies?

A: Success is measured differently depending on the indication. For example, in a study evaluating relief from nighttime heartburn, Levant significantly increased the mean percentage of nights without heartburn when compared to a placebo.

How should Levant be stored and disposed of?

Official Storage and Disposal Requirements for Levant (Lansoprazole)

Levant must be stored according to regulatory specifications to ensure product stability. The required storage environment is Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F), with permitted excursions.

Key Storage Constraints

Constraint Requirement
Temperature Keep from freezing or high heat.
Protection Keep the container tightly closed to protect from moisture and high humidity.
Child Safety Must be kept out of the reach of children.

Disposal of expired or unused Levant should follow official guidelines. The FDA recommends using a drug take-back program. If a take-back option is unavailable, the product should be mixed with an undesirable substance, placed in a sealed bag, and discarded with household trash. Levant is not on the list of medicines authorized for flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Levant found in:

A-Z Index: